Silvercrest Asset Management Group LLC Has $9.92 Million Position in Phreesia, Inc. (NYSE:PHR)

Silvercrest Asset Management Group LLC increased its holdings in shares of Phreesia, Inc. (NYSE:PHR) by 31.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 394,352 shares of the company’s stock after acquiring an additional 93,349 shares during the quarter. Silvercrest Asset Management Group LLC owned about 0.68% of Phreesia worth $9,922,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Invesco Ltd. increased its holdings in shares of Phreesia by 0.9% during the 4th quarter. Invesco Ltd. now owns 40,249 shares of the company’s stock worth $1,013,000 after acquiring an additional 357 shares during the last quarter. NewEdge Advisors LLC boosted its holdings in shares of Phreesia by 12.1% during the 4th quarter. NewEdge Advisors LLC now owns 4,256 shares of the company’s stock worth $107,000 after buying an additional 459 shares during the period. Johnson Financial Group Inc. boosted its holdings in shares of Phreesia by 381.3% during the 4th quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company’s stock worth $28,000 after buying an additional 896 shares during the period. R Squared Ltd bought a new stake in shares of Phreesia during the 4th quarter worth about $30,000. Finally, BankPlus Trust Department bought a new stake in shares of Phreesia during the 4th quarter worth about $34,000. 92.10% of the stock is owned by institutional investors and hedge funds.

Phreesia Stock Performance

NYSE:PHR opened at $25.34 on Friday. The stock has a fifty day moving average price of $25.29 and a 200-day moving average price of $24.99. The company has a market cap of $1.49 billion, a price-to-earnings ratio of -17.24 and a beta of 0.74. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $30.53.

Insider Activity

In other news, CFO Balaji Gandhi sold 8,045 shares of the company’s stock in a transaction on Tuesday, April 8th. The stock was sold at an average price of $23.85, for a total transaction of $191,873.25. Following the completion of the sale, the chief financial officer now directly owns 108,411 shares in the company, valued at approximately $2,585,602.35. This represents a 6.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel Allison C. Hoffman sold 1,213 shares of the company’s stock in a transaction on Wednesday, April 16th. The shares were sold at an average price of $23.81, for a total value of $28,881.53. Following the sale, the general counsel now owns 137,921 shares of the company’s stock, valued at approximately $3,283,899.01. The trade was a 0.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 55,260 shares of company stock worth $1,406,251. 5.80% of the stock is currently owned by company insiders.

Analyst Ratings Changes

PHR has been the subject of several research analyst reports. Piper Sandler reaffirmed an “overweight” rating and set a $33.00 target price (up previously from $31.00) on shares of Phreesia in a report on Wednesday, January 29th. Canaccord Genuity Group boosted their price target on Phreesia from $34.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, March 13th. DA Davidson decreased their price objective on Phreesia from $36.00 to $34.00 and set a “buy” rating on the stock in a report on Monday, April 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Phreesia in a report on Thursday, March 13th. Finally, KeyCorp decreased their price objective on Phreesia from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Wednesday, April 16th. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $31.33.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.